Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study.

Feasibility Measurement Methamphetamine Sleep Withdrawal

Journal

European addiction research
ISSN: 1421-9891
Titre abrégé: Eur Addict Res
Pays: Switzerland
ID NLM: 9502920

Informations de publication

Date de publication:
18 Mar 2024
Historique:
received: 27 09 2023
accepted: 21 12 2023
medline: 19 3 2024
pubmed: 19 3 2024
entrez: 18 3 2024
Statut: aheadofprint

Résumé

Sleep disturbance is common during methamphetamine (MA) use and withdrawal; however, the feasibility of combined subjective-objective measurement of sleep-wake has not been shown in this population. Actigraphy is a well-established, non-invasive measure of sleep-wake cycles with good concordance with polysomnography. This study aimed to investigate the feasibility and utility of using actigraphy and sleep diaries to investigate sleep during MA withdrawal. We conducted a feasibility and utility study of actigraphy and sleep diaries during a clinical trial of lisdexamfetamine for MA withdrawal. Participants were inpatients for 7 days, wore an actigraph (Philips Actiwatch 2) and completed a modified Consensus Sleep Diary each morning. Participants were interviewed between days 3-5. Ten participants (mean age 37 years, 90% male) were enrolled. No participant removed the device prematurely. Participants interviewed (n = 8) reported that the actigraph was not difficult or distracting to wear or completion of daily sleep diary onerous. Actigraphic average daily sleep duration over 7 days was 568 min, sleep onset latency 22.4 min, wake after sleep onset (WASO) 75.2 min, and sleep efficiency 83.6%. Sleep diaries underreported daily sleep compared with actigraphy (sleep duration was 56 min (p = 0.008) and WASO 47 min (p < 0.001) less). Overall sleep quality was 4.4 on a nine-point Likert scale within the diary. Continuous actigraphy is feasible to measure sleep-wake in people withdrawing from MA, with low participant burden. We found important differences in self-reported and actigraphic sleep, which need to be explored in more detail.

Identifiants

DOI: 10.1159/000536328 PMID: 38498995
pubmed: 38498995
pii: 000536328
doi: 10.1159/000536328
doi:

Types de publication

News

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-5

Informations de copyright

© 2024 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Liam S Acheson (LS)

The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Sydney, New South Wales, Australia.
Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney, New South Wales, Australia.

Christopher Gordon (C)

Susan Wakil School of Nursing and Midwifery, The University of Sydney, Sydney, New South Wales, Australia.
CIRUS Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.

Rebecca McKetin (R)

The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Sydney, New South Wales, Australia.

Jonathan Brett (J)

Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
St. Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia.

Michael Christmass (M)

Next Step Drug and Alcohol Services, Perth, Washington, Australia.
National Drug Research Institute, Curtin University, Perth, Washington, Australia.

Craig Rodgers (C)

Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.

Nicholas Lintzeris (N)

New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, New South Wales, Australia.
Drug and Alcohol Services, Sydney, New South Wales, Australia.
Specialty of Addiction Medicine, The University of Sydney, Sydney, New South Wales, Australia.

Adrian Dunlop (A)

New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, New South Wales, Australia.
Drug and Alcohol Clinical Services, Newcastle, New South Wales, Australia.
School of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, Australia.

Michael Farrell (M)

The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Sydney, New South Wales, Australia.

Steven Shoptaw (S)

Department of Family Medicine, The University of California Los Angeles, Los Angeles, California, USA.

Nadine Ezard (N)

Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney, New South Wales, Australia.
New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, New South Wales, Australia.

Krista J Siefried (KJ)

The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Sydney, New South Wales, Australia.
Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney, New South Wales, Australia.

Classifications MeSH